Gain Therapeutics (GANX) Total Debt (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Total Debt of $373546.0 for Q1 2026, down 12.64% year-over-year from $427597.0 in Q1 2025, and down 6.84% quarter-over-quarter from $400953.0 in Q4 2025.
Gain Therapeutics (GANX) Total Debt (2020 - 2026) Analysis & Trends
Gain Therapeutics' Total Debt history runs 7 years deep, the most recent figure standing at $373546.0 for Q1 2026.
- In Q1 2026, Total Debt fell 12.64% year-over-year to $373546.0; the TTM figure through Mar 2026 stood at $373546.0 (down 12.64% YoY), while the FY2025 annual figure was $400953.0, down 8.56% from the prior year.
- Total Debt for Q1 2026 stood at $373546.0, down from $400953.0 in the prior quarter.
- The five-year high for Total Debt was $647513.0 in Q1 2022, with the low at $373546.0 in Q1 2026.
- The 5-year median for Total Debt is $507684.0 (2024), against an average of $514408.5.
- The sharpest annual moves came in 2023 and 2024: Total Debt dropped 5.89% in 2023, then fell 22.78% in 2024.
- Gain Therapeutics' Total Debt stood at $603393.0 in 2022, then decreased by 5.89% to $567850.0 in 2023, then declined by 22.78% to $438504.0 in 2024, then decreased by 8.56% to $400953.0 in 2025, then retreated by 6.84% to $373546.0 in 2026.
- Business Quant data shows GANX's Total Debt at $373546.0 in Q1 2026, $400953.0 in Q4 2025, and $424342.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.34 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 770.36 Mn |
| 10 | Gain Therapeutics | 85.12 Mn | 85.12 Mn | - | 343,686.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 343,686.00 |
| Mar 31, 2026 | 373,546.00 |
| Dec 31, 2025 | 400,953.00 |
| Sep 30, 2025 | 424,342.00 |
| Jun 30, 2025 | 451,467.00 |
| Mar 31, 2025 | 427,597.00 |
| Dec 31, 2024 | 438,504.00 |
| Sep 30, 2024 | 494,410.00 |
| Jun 30, 2024 | 486,403.00 |
| Mar 31, 2024 | 507,684.00 |
| Dec 31, 2023 | 567,850.00 |
| Sep 30, 2023 | 544,219.00 |
| Jun 30, 2023 | 578,274.00 |
| Mar 31, 2023 | 587,496.00 |
| Dec 31, 2022 | 603,393.00 |
| Sep 30, 2022 | 585,283.00 |
| Jun 30, 2022 | 626,010.00 |
| Mar 31, 2022 | 647,513.00 |
| Dec 31, 2021 | 694,294.00 |
| Sep 30, 2021 | 706,812.00 |